Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Change in Receivables of -$340000.0 in Q4 2025, down 535.9% quarter-over-quarter from $78000.0 in Q3 2025, and up 47.37% on a YoY basis from -$230714.3 in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Change in Receivables history runs 16 years deep, the most recent figure standing at -$340000.0 for Q4 2025.
- In Q4 2025, Change in Receivables rose 47.37% year-over-year to -$340000.0; the TTM figure through Dec 2025 stood at -$261000.0 (down 24.29% YoY), while the FY2025 annual figure was -$434000.0, down 288.7% from the prior year.
- Change in Receivables was -$340000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from $78000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $596000.0 in Q4 2023 to a low of -$2.1 million in Q1 2021.
- Historically, Change in Receivables has averaged -$218050.0 across 5 years, with a median of -$17000.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables jumped 346.07% in 2024, then sank 2488.89% in 2025.
- A 5-year view of Change in Receivables shows it stood at -$537000.0 in 2021, then jumped by 46.18% to -$289000.0 in 2022, then soared by 306.23% to $596000.0 in 2023, then slumped by 208.39% to -$646000.0 in 2024, then surged by 47.37% to -$340000.0 in 2025.
- The last three Change in Receivables figures came in at -$340000.0 (Q4 2025), $78000.0 (Q3 2025), and $216000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -78.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 106.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -38.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 81.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 23.22 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 116.25 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.23 Mn |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | -340,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -340,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 596,000.00 |
| Dec 31, 2023 | 596,000.00 |
| Sep 30, 2023 | -184,000.00 |
| Sep 30, 2023 | -184,000.00 |